Real-world experience with pembrolizumab toxicities in advanced melanoma patients: a single-center experience in the UK.

IF 1 Q4 ONCOLOGY

Melanoma Management Pub Date : 2018-04-24 eCollection Date: 2018-06-01 DOI:10.2217/mmt-2017-0028

Alfred Cp So, Ruth E Board

引用次数: 24

Abstract

Aim: We aimed to characterize the safety profile of pembrolizumab in advanced melanoma patients at our center to better reflect 'real-world' data on anti-PD-1 inhibitors.

Materials & methods: At our institution, 58 ipilimumab-naive and 30 ipilimumab-treated patients with advanced melanoma who have received pembrolizumab between June 2014 and June 2017 were included for analysis.

Results: Incidence of any-grade and grade 3/4 toxicities were 81.8% (n = 72) and 12.5% (n = 11), respectively. The most common side effects were skin-related (61.4%, n = 54) and gastrointestinal-related (51.1%, n = 45) events. In total, 25% of patients required oral steroids to manage immune-related adverse events with a median cumulative prednisolone dose of 683 mg (range: 40-3745 mg).

Conclusion: Pembrolizumab is well tolerated in 'real-world' patients and severe toxicities can be effectively managed with systemic steroids.

Abstract Image

查看原文本刊更多论文

pembrolizumab对晚期黑色素瘤患者毒性的真实世界经验:英国的单中心经验

目的:我们旨在描述pembrolizumab在本中心晚期黑色素瘤患者中的安全性，以更好地反映抗pd -1抑制剂的“真实”数据。材料与方法:本研究纳入了2014年6月至2017年6月期间接受派姆单抗治疗的58例伊匹单抗初治和30例伊匹单抗治疗的晚期黑色素瘤患者进行分析。结果:任意级和3/4级毒性发生率分别为81.8% (n = 72)和12.5% (n = 11)。最常见的副作用是皮肤相关(61.4%，n = 54)和胃肠道相关(51.1%，n = 45)事件。总的来说，25%的患者需要口服类固醇来控制免疫相关不良事件，泼尼松龙的中位累积剂量为683毫克(范围:40-3745毫克)。结论:Pembrolizumab在“现实世界”患者中耐受性良好，严重毒性可以通过全身类固醇有效控制。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Melanoma Management ONCOLOGY-

CiteScore

5.10

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： Skin cancer is on the rise. According to the World Health Organization, 132,000 melanoma skin cancers occur globally each year. While early-stage melanoma is usually relatively easy to treat, once disease spreads prognosis worsens considerably. Therefore, research into combating advanced-stage melanoma is a high priority. New and emerging therapies, such as monoclonal antibodies, B-RAF and KIT inhibitors, antiangiogenic agents and novel chemotherapy approaches hold promise for prolonging survival, but the search for a cure is ongoing. Melanoma Management publishes high-quality peer-reviewed articles on all aspects of melanoma, from prevention to diagnosis and from treatment of early-stage disease to late-stage melanoma and metastasis. The journal presents the latest research findings in melanoma research and treatment, together with authoritative reviews, cutting-edge editorials and perspectives that highlight hot topics and controversy in the field. Independent drug evaluations assess newly approved medications and their role in clinical practice. Key topics covered include: Risk factors, prevention and sun safety education Diagnosis, staging and grading Surgical excision of melanoma lesions Sentinel lymph node biopsy Biological therapies, including immunotherapy and vaccination Novel chemotherapy options Treatment of metastasis Prevention of recurrence Patient care and quality of life.